BridgeMD
Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder
EU CTIS ID: 2024-515475-35-00
What this study is testing
The central research question of this project is whether a combination of (food) exposure with response prevention (ERP) and cortisol is superior to ERP under placebo in terms of the reduction of craving for food in Binge Eating Disorder (BED).
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients with BED according to DSM-5
- Male or female patients aged between 18 and 40 (the upper age limit was chosen to minimise potential confounding effects by hormonal changes related to menopause)
- Written informed consent obtained according to international guidelines and local laws
- Ability to understand the nature of the trial and the trial related procedures and to comply with them.
You likely can't join if
- systemic (i.v. or oral) glucocorticoid treatment within the last 3 months
- known pheochromocytoma
- Simultaneous participation in another interventional trial
- Pregnant or breastfeeding females
- current diagnosis of a psychotic, bipolar, or substance use disorder
- severe somatic illness (e.g. cancer, cardiovascular disease, instable diabetes mellitus; blood pressure ≥ 160/100 mmHg at rest and/or current treatment of hypertensive crisis within last 6 months)
See the full eligibility criteria
- Patients with BED according to DSM-5
- Male or female patients aged between 18 and 40 (the upper age limit was chosen to minimise potential confounding effects by hormonal changes related to menopause)
- Written informed consent obtained according to international guidelines and local laws
- Ability to understand the nature of the trial and the trial related procedures and to comply with them.
- systemic (i.v. or oral) glucocorticoid treatment within the last 3 months
- known pheochromocytoma
- Simultaneous participation in another interventional trial
- Pregnant or breastfeeding females
- current diagnosis of a psychotic, bipolar, or substance use disorder
- severe somatic illness (e.g. cancer, cardiovascular disease, instable diabetes mellitus; blood pressure ≥ 160/100 mmHg at rest and/or current treatment of hypertensive crisis within last 6 months)
- current or planned use of psychotropic medication (during the period of the study)
- current or planned psychotherapy (during the period of the study)
- known hypersensitivity to hydrocortisone
- known hereditary galactose intolerance
- known lactase deficiency
- known glucose-galactose malabsorption
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.